<DOC>
	<DOC>NCT01083173</DOC>
	<brief_summary>This single-arm, multi-center, Post-Marketing Surveillance study of Kaletra (lopinavir/ritonavir) was conducted in accordance with the approved Korean product labeling in participants 2 years of age and older with human immunodeficiency virus type 1 (HIV-1) infection.</brief_summary>
	<brief_title>Surveillance of Kaletra in Korean Patients</brief_title>
	<detailed_description>Participants were observed for up to 48 weeks following the first dose of Kaletra. A follow-up visit took place 1-2 weeks after treatment initiation, and subsequent visits occurred at the discretion of the investigators, typically occurring every 3 months. Clinical/immunological/virological/laboratory status, Kaletra-containing regimen/concomitant medication information, and adverse event information were obtained at follow-up visits.</detailed_description>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patients 2 years of age and above with HIV1 infection Patients who were prescribed Kaletra treatment as per investigator's medical judgment Patients who gave verbal or written authorization to use their personal and health data Patients who started Kaletra treatment after study agreement was in place Patients with known hypersensitivity to lopinavir, ritonavir or any excipients of the Kaletra tablet Patients who were being treated or will be treated with drugs that are contraindicated with Kaletra Patients who have been treated with Kaletra Patients participating in other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Postmarketing Drug Surveillance</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>Kaletra</keyword>
</DOC>